Incidence of infections with BCMA-directed CAR T-cell therapies as reported in clinical studies (A) and in retrospective real-world series (B) (Continued)
| 8B . | |||||||
|---|---|---|---|---|---|---|---|
| Real-world cohorts . | Number of patients . | Time frame . | Overall grade (%) . | Bacterial (%) . | Viral (%) . | Fungal (%) . | Respiratory infection . |
| Kambhampti76 | 55 | 12 mo | 47 infections in 29 patients (53%) | 40 | 53 | 6 | 68 |
| Logue77 | 52 | 100 d | 46 infectious events in 28 patients (54%) | 59 | 35 | 9 | 59 |
| Wang78 | 40 | Until last FU; median FU 16 mo | 44 infectious events in 23 patients (58%) | 57 | 18 | 7 | 73 |
| Josyula79 | 32 | 180 d | 23 infectious events in 17 patients (53%) | 30 | 61 | 9 | NR |
| Mohan71 | 26 | Median FU 9 mo | 5 patients with infection (19%) | NR | NR | NR | NR |
| Mikkilineni80 | 24 | 30 d | 10 infectious events in 9 patients (38%) | 90 | 10 | 0 | NR |
| Little81 | 99 | 365 d | d 1-100; 42 infectious events in 26 patients (26%) d 101-365; 22 infectious events in 15 patients (15%) | 69 27 | 17 41 | 7 0 | a b |
| 8B . | |||||||
|---|---|---|---|---|---|---|---|
| Real-world cohorts . | Number of patients . | Time frame . | Overall grade (%) . | Bacterial (%) . | Viral (%) . | Fungal (%) . | Respiratory infection . |
| Kambhampti76 | 55 | 12 mo | 47 infections in 29 patients (53%) | 40 | 53 | 6 | 68 |
| Logue77 | 52 | 100 d | 46 infectious events in 28 patients (54%) | 59 | 35 | 9 | 59 |
| Wang78 | 40 | Until last FU; median FU 16 mo | 44 infectious events in 23 patients (58%) | 57 | 18 | 7 | 73 |
| Josyula79 | 32 | 180 d | 23 infectious events in 17 patients (53%) | 30 | 61 | 9 | NR |
| Mohan71 | 26 | Median FU 9 mo | 5 patients with infection (19%) | NR | NR | NR | NR |
| Mikkilineni80 | 24 | 30 d | 10 infectious events in 9 patients (38%) | 90 | 10 | 0 | NR |
| Little81 | 99 | 365 d | d 1-100; 42 infectious events in 26 patients (26%) d 101-365; 22 infectious events in 15 patients (15%) | 69 27 | 17 41 | 7 0 | a b |
Plus 7% pneumonia not otherwise specified. Overall, 13 of 42 (31%) of early infectious events were respiratory infections involving the lungs, upper respiratory tract, or sinuses.
Plus 32% pneumonia not other specified. Overall 17 of 22 (77%) of late infectious events were composed of respiratory infections involving the lungs, upper respiratory tract, or sinuses.
FU, follow-up.